This case-based live virtual activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy.
This initiative is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses and other healthcare professionals and teams involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.
Upon completion of the program, attendees should be able to:
- Review mechanisms of action and clinical profiles of immunotherapies used alone or in combination across lines of therapy for the treatment of HCC
- Recognize and manage side effects and toxicities associated with available and emerging immunotherapies used alone or in combination across lines of therapy for the treatment of HCC
- Discuss established and potential prognostic and predictive immune- and non-immune-related biomarkers for HCC and their impact on patient management strategies
- Summarize current recommendations and emerging evidence regarding the use of immunotherapies for patients with HCC during the COVID-19 pandemic including the management of irAEs and the utility of telemedicine
- Explain patient-centered SDM approaches aimed at optimizing cancer care and survivorship for those with HCC and the role of emergency care physicians as part of multidisciplinary teams in the diagnosis and management of irAEs associated with immunotherapies used alone or in combination
ACCREDITATION AND DESIGNATION STATEMENTS
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Med Learning Group designates this live virtual activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.
Nursing Credit Information
Purpose: This program would be beneficial for nurses involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy.
Credits: 1.0 ANCC Contact Hour
Ultimate Medical Academy/Complete Conference Management (CCM) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
ABIM Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Robert G. Gish, MD, FAASLD, AGAF, FAST
Professor of Medicine, Loma Linda University, Liver Transplant Institute, Las Vegas, NV Principal, Robert G Gish Consultants, LLC
Adjunct Professor of Medicine, University of Nevada, Reno
Adjunct Professor of Medicine, University of Nevada, Las Vegas
Adjunct Professor of Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego
Medical Director, Hepatitis B Foundation, Doylestown, PA
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF FINANCIAL RELATIONSHIPS
Dr. Gish reports the following disclosures:
Grants/Research Support: Gilead; Consultant and/or Advisor: Abbott, AbbVie, Access Biologicals, Antios, Arrowhead, Bayer AG, Bristol-Myers Squibb Company, Dova, Dynavax, Eiger, Eisai, Enyo, eStudySite, Forty-Seven Inc, Genentech, Genlantis, Gerson Lehrman Group, Gilead Sciences, HepaTX, HepQuant, Intercept, Janssen, Helios, Lilly, Merck, Salix, Shionogi, and Viking Therapeutics; Current Activity with Scientific or Clinical Advisory Boards: Abbott, AbbVie, Merck, Arrowhead, Bayer, Dova Pharmaceuticals, Eiger, Enyo, HepQuant, Intercept, and Janssen; Clinical Trials Alliance: Topography Health; Advisory Board: Prodigy; Advisory Consultant: Biocollections, Fujifilm/Wako, and Quest; Data Safety Monitoring Board: Arrowhead; Consulting Confidentiality Agreements: Abbvie, Abbott, Access Biologicals, ADMA Biologics, AEC Partners, Aligos Therapeutics, Arena Pharmaceuticals Inc, Arrowhead, Arterys Inc Alexion, Altimmune, Antios Therapeutics, AprosTx, Bayer, Cirina, Consumer Health Products Assoc, Dova Pharmaceuticals, DRG Abacus, DURECT Corporation, Dynavax, Echosens, Eiger, Enyo, Exelixis, Forty-Seven Inc, Fujifilm Wako Diagnostics, Gilead, HepQuant, HepaTx, IDLogiq, Intellia, Intercept, Inotek, Iqvia, Janssen/J&J, KannaLife, Laboratory for Advanced Medicine, Labyrinth Holdings, Lilly, MedImmune, Merck, New Enterprise Associates, Ogilvy CommonHealth, Organovo, Patient Connect, ProdigY Biotech, Prometheus Laboratories, Refuah Solutions, Regulus Therapeutics, Salix, Shionogi Inc, Spring Bank, and Trimaran; Speakers Bureau: AbbVie, Bayer, BMS, Eisai, Gilead Sciences Inc., Intercept, and Salix; Minor stock shareholder: RiboSciences, and CoCrystal; Stock Options: Eiger, Genlantis, HepQuant, and AngioCrine; Expert Testimony for Pharma (Intellectual Property): Janssen and USP Pharma
Staff, Planners and Managers
The independent reviewers, staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests:
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
Brianna Hanson, Outcomes and Accreditation Coordinator for Med Learning Group has nothing to disclose.
Debra Gordon, MS, Medical Director for Med Learning Group has nothing to disclose.
Melissa A. Johnson, Senior Program Manager for Med Learning Group has nothing to disclose.
Jessica McMullen, MPH, Program Manager for Med Learning Group has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CNE credit for the live virtual activity. To receive CME/CNE credit participants must:
- Read the CME/CNE information and faculty disclosures.
- Participate in the live virtual activity.
- Complete the online post-test and evaluation.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at email@example.com.
RELEASE DATE: July 28, 2021
EXPIRATION DATE: July 28, 2022
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at firstname.lastname@example.org.
Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.